PT-141 (Bremelanotide) Research Overview: Melanocortin and Sexual Function
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan II. It acts as an agonist at melanocortin receptors (MCRs), particularly MC3R and MC4R, which are expressed in the central nervous system and play a role in sexual arousal and function.
PT-141 holds the distinction of being the first peptide drug approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women (approved as Vyleesi in 2019).
Mechanism of Action
PT-141 mechanism differs fundamentally from other sexual function compounds:
Central (CNS) mechanism: Unlike PDE5 inhibitors that work peripherally on vascular smooth muscle, PT-141 acts centrally in the brain by activating MC3R and MC4R receptors in the hypothalamus.
Dopaminergic activation: MC4R activation in the hypothalamus triggers dopamine release in the mesolimbic pathway, which is associated with motivation, reward, and sexual arousal.
Oxytocin release: Research has shown that melanocortin receptor activation can stimulate oxytocin release from the paraventricular nucleus.
No vascular mechanism: PT-141 does not directly affect blood pressure or vascular smooth muscle.
Clinical Research
Phase 2 (Male Sexual Dysfunction): Early clinical trials in men with erectile dysfunction demonstrated that PT-141 produced significant improvements in erectile function compared to placebo, including in men who had not responded to PDE5 inhibitors.
Phase 3 (Female HSDD): Multiple Phase 3 trials in premenopausal women with HSDD demonstrated that PT-141 significantly increased the number of satisfying sexual events and reduced distress related to low sexual desire.
FDA Approval (2019): Bremelanotide (Vyleesi) was approved by the FDA for HSDD in premenopausal women, administered as a subcutaneous injection 45 minutes before anticipated sexual activity.
Pharmacokinetics
| Parameter | Value | |-----------|-------| | Route | Subcutaneous injection | | Time to peak | 1 hour | | Half-life | ~2.7 hours | | Duration of effect | 6-12 hours |
Comparison with Melanotan II
| Parameter | PT-141 | Melanotan II | |-----------|--------|-------------| | Receptor selectivity | MC3R, MC4R (selective) | MC1R, MC3R, MC4R, MC5R (non-selective) | | Tanning effect | Minimal | Significant (MC1R) | | Sexual function | Primary effect | Secondary effect | | FDA status | Approved (HSDD) | Not approved |
Summary
PT-141 (bremelanotide) represents a landmark in peptide pharmacology. Its unique CNS mechanism, distinct from peripheral vascular approaches, makes it a valuable research tool for studying the melanocortin system, dopaminergic reward pathways, and the neurobiology of sexual function.
See Also: Peptide Research Glossary: Key Terms and Definitions | Research Peptides for Beginners: Complete Guide
Was this article helpful?
Click a star to rate